Browsing by Author "Arab Verdugo, Juan Pablo"

Now showing 1 - 20 of 58
  • No Thumbnail Available
    Item
    A Precision Medicine Guided Approach to the Utilization of Biomarkers in MASLD
    (2024) Thakral, Nimish; Desalegn, Hailemichael; Diaz Piga, Luis Antonio; Cabrera, Daniel; Loomba, Rohit; Arrese Jiménez, Marco Antonio; Arab Verdugo, Juan Pablo
    The new nomenclature of metabolic dysfunction-associated steatotic liver disease (MASLD) emphasizes a positive diagnosis based on cardiometabolic risk factors. This definition is not only less stigmatizing but also allows for subclassification and stratification, thereby addressing the heterogeneity of what was historically referred to as nonalcoholic fatty liver disease. The heterogeneity within this spectrum is influenced by several factors which include but are not limited to demographic/dietary factors, the amount of alcohol use and drinking patterns, metabolic status, gut microbiome, genetic predisposition together with epigenetic factors. The net effect of this dynamic and intricate system-level interaction is reflected in the phenotypic presentation of MASLD. Therefore, the application of precision medicine in this scenario aims at complex phenotyping with consequent individual risk prediction, development of individualized preventive strategies, and improvements in the clinical trial designs. In this review, we aim to highlight the importance of precision medicine approaches in MASLD, including the use of novel biomarkers of disease, and its subsequent utilization in future study designs.
  • Thumbnail Image
    Item
    Achieving protection against HBV in HIV patients: Finding the best strategy
    (2016) Vargas J.; Arab Verdugo, Juan Pablo; Jensen D.; Fuster F.
  • Thumbnail Image
    Item
    Alcohol-related liver disease : Clinical practice guidelines by the Latin American Association for the Study of the Liver (ALEH)
    (2019) Arab Verdugo, Juan Pablo; Roblero, J.P.; Altamirano, J.; Bessone, F.; Araujo, R.C.; Higuera-De la Tijera, F.; Restrepo, J.C.; Torre, A.; Urzua, A.; Simonetto, D.A.; Abraldes, J.G.; Mendez-Sanchez, N.; Contreras, F.; Lucey, M.R.; Shah, V.H.; Cortez-Pinto, H.; Bataller, R.
  • Thumbnail Image
    Item
    Alcohol-Related Liver Disease in Latin America: Local Solutions for a Global Problem
    (John Wiley and Sons Inc, 2020) Díaz Piga, Luis Antonio; Roblero Cum, Juan Pablo; Bataller, Ramon; Arab Verdugo, Juan Pablo
  • Thumbnail Image
    Item
    An Open-Label, Dose-Escalation Study to Assess the Safety and Efficacy of IL-22 Agonist F-652 in Patients With Alcohol-associated Hepatitis
    (2020) Arab Verdugo, Juan Pablo; Sehrawat, T. S.; Simonetto, D. A.; Verma, V. K.; Feng, D. C.; Tang, T.; Dreyer, K.; Yan, X. Q.; Daley, W. L.; Ibacache Figueroa, Mauricio Enrique; Sanyal, A.; Chalasani, N.; Radaeva, S.; Yang, L.; Vargas, H.; Gao, B.; Gores, G. J.; Malhi, H.; Kamath, P. S.; Shah, V. H.
  • Thumbnail Image
    Item
    Andrographolide Ameliorates Inflammation and Fibrogenesis and Attenuates Inflammasome Activation in Experimental Non-Alcoholic Steatohepatitis
    (2017) Cabrera, Daniel; Wree, Alexander; Povero, Davide; Solís, Nancy; Hernández, Alejandra; Pizarro Rojas, Margarita Alicia; Moshage, Han; Torres Montes, Paula Javiera; Feldstein, Ariel E.; Cabello Verrugio, Claudio Alejandro; Brandan, Enrique; Barrera Martínez, Francisco Javier; Arab Verdugo, Juan Pablo; Arrese Jiménez, Marco
  • Thumbnail Image
    Item
    La asociación de un probiótico al régimen de erradicación de Helicobacter pylori no aumenta la eficacia ni disminuye los efectos adversos del tratamiento
    (2015) Zamora Helo, Maximiliano; Herrera A., Sofía; Yañez C., Gonzalo; Arab Verdugo, Juan Pablo; Riquelme Pérez, Arnoldo; Zamora H., Maximiliano; Herrera A., Sofía; Yañez C., Gonzalo; Arab Verdugo, Juan Pablo; Riquelme Pérez, Arnoldo
  • Thumbnail Image
    Item
    Association between public health policies on alcohol and worldwide cancer, liver disease and cardiovascular disease outcomes
    (Elsevier B.V., 2023) Diaz Piga, Luis Antonio; Fuentes, López Eduardo; Idalsoaga Ferrer, Francisco Javier; Ayares Campos, Gustavo Ignacio; Corsi Sotelo, Oscar Felipe; Arnold Alvarez, Jorge Ignacio; Cannistra Cadiz, Macarena Rossella; Vio Quiroz, Danae Fernanda; Marquez Lomas, Andrea; Ramirez Cadiz, Carolina Andrea; Medel Salas, María Paz; Hernández Tejero, María; Ferreccio Readi, Fresia Catterina; Lazo Bravo, Mariana Carolina; Roblero Cum, Juan Pablo; Cotter, Thomas G.; Kulkarni ,Anand V.; Kim, Won; Brahmania, Mayur; Louvet, Alexandre; Tapper, Elliot B.; Dunn, Winston; Simonetto, Douglas; Shah, Vijay H.; Kamath, Patrick S.; Lazarus, Jeffrey V.; Singal, Ashwabi K.; Bataller, Ramón; Arrese Jimenez, Marco Antonio; Arab Verdugo, Juan Pablo
    © 2023 The Author(s)Background & Aims: The long-term impact of alcohol-related public health policies (PHPs) on disease burden is unclear. We aimed to assess the association between alcohol-related PHPs and alcohol-related health consequences. Methods: We conducted an ecological multi-national study including 169 countries. We collected data on alcohol-related PHPs from the WHO Global Information System of Alcohol and Health 2010. Data on alcohol-related health consequences between 2010–2019 were obtained from the Global Burden of Disease database. We classified PHPs into five items, including criteria for low, moderate, and strong PHP establishment. We estimated an alcohol preparedness index (API) using multiple correspondence analysis (0 lowest and 100 highest establishment). We estimated an incidence rate ratio (IRR) for outcomes according to API using adjusted multilevel generalized linear models with a Poisson family distribution. Results: The median API in the 169 countries was 54 [IQR 34.9–76.8]. The API was inversely associated with alcohol use disorder (AUD) prevalence (IRR 0.13; 95% CI 0.03–0.60; p = 0.010), alcohol-associated liver disease (ALD) mortality (IRR 0.14; 95% CI 0.03–0.79; p = 0.025), mortality due to neoplasms (IRR 0.09; 95% CI 0.02–0.40; p = 0.002), alcohol-attributable hepatocellular carcinoma (HCC) (IRR 0.13; 95% CI 0.02–0.65; p = 0.014), and cardiovascular diseases (IRR 0.09; 95% CI 0.02–0.41; p = 0.002). The highest associations were observed in the Americas, Africa, and Europe. These associations became stronger over time, and AUD prevalence was significantly lower after 2 years, while ALD mortality and alcohol-attributable HCC incidence decreased after 4 and 8 years from baseline API assessment, respectively (p <0.05). Conclusions: The API is a valuable instrument to quantify the robustness of alcohol-related PHP establishment. Lower AUD prevalence and lower mortality related to ALD, neoplasms, alcohol-attributable HCC, and cardiovascular diseases were observed in countries with a higher API. Our results encourage the development and strengthening of alcohol-related policies worldwide. Impact and implications: We first developed an alcohol preparedness index, an instrument to assess the existence of alcohol-related public policies for each country. We then evaluated the long-term association of the country's alcohol preparedness index in 2010 with the burden of chronic liver disease, hepatocellular carcinoma, other neoplasms, and cardiovascular disease. The strengthening of alcohol-related public health policies could impact long-term mortality rates from cardiovascular disease, neoplasms, and liver disease. These conditions are the main contributors to the global burden of disease related to alcohol use. Over time, this association has not only persisted but also grown stronger. Our results expand the preliminary evidence regarding the importance of public health policies in controlling alcohol-related health consequences.
  • Thumbnail Image
    Item
    Baveno VI and Expanded Baveno VI criteria successfully predicts the absence of high-risk gastro-oesophageal varices in a Chilean cohort
    (2020) Gaete Celis, María Isabel; Díaz Piga, Luis Antonio; Arenas Fajardo, Cristian Alexis; Gonzalez, K.; Cattaneo, M.; Soza, Alejandro; Arrese, Marco; Barrera Martínez, Francisco José; Arab Verdugo, Juan Pablo; Benítez, Carlos; Fuster, F.; Henriquez, R.
  • Thumbnail Image
    Item
    Beneficial effects of mineralocorticoid receptor blockade in experimental non-alcoholic steatohepatitis
    (2015) Pizarro, M.; Solís, Nancy; Quintero, P.; Barrera Martínez, Francisco José; Cabrera, D.; Rojas-de Santiago, P.; Arab Verdugo, Juan Pablo; Padilla, O.; Roa Strauch, Juan Carlos Enrique; Moshage, H.; Wree, A.; Inzaugarat, E.; Feldstein, A.; Fardella B., Carlos; Baudrand Biggs, René; Riquelme, A.; Arrese Jiménez, Marco
  • Thumbnail Image
    Item
    Bile acids and portal hypertension
    (2017) Arab Verdugo, Juan Pablo; Barrera Martínez, Francisco José; Arrese Jiménez, Marco
  • Thumbnail Image
    Item
    Bile Acids in Cholestasis and its Treatment
    (2017) Arab Verdugo, Juan Pablo; Cabrera, D.; Arrese Jiménez, Marco
  • Thumbnail Image
    Item
    Black hairy tongue during interferon therapy for hepatitis C
    (2015) Arab Verdugo, Juan Pablo; Vargas, J.; Morales, C.; Arrese Jiménez, Marco; Arab Verdugo, Juan Pablo; Vargas, J.; Morales, C.; Arrese Jiménez, Marco
  • Thumbnail Image
    Item
    CD4/CD8 ratio as a predictor of the response to HBV vaccination in HIV-positive patients : a prospective cohort study
    (2016) Acuña, P.; Peirano, F.; Fuster, F.; Arab Verdugo, Juan Pablo; Martínez, F.; Sabrina, Soto; Ahumada, Rodrigo; Jensen, Werner; Fuster, F.; Vargas Domínguez, José Ignacio; Jensen, D.; Sarmiento, V.
  • Thumbnail Image
    Item
    Chemical hypoxia induces pro-inflammatory signals in fat-laden hepatocytes and contributes to cellular crosstalk with Kupffer cells through extracellular vesicles
    (2020) Hernández Villanueva, Alejandra Andrea; Geng, Y.; Sepúlveda, R.; Solis López, Nancy de las Mercedes; Torres, J.; Arab Verdugo, Juan Pablo; Barrera Martínez, Francisco Javier; Cabrera, D.; Moshage, H.; Arrese, Marco
  • Thumbnail Image
    Item
    Circulating extracellular vesicles carrying sphingolipid cargo for the diagnosis and dynamic risk profiling of alcoholic hepatitis
    (2021) Sehrawat, T. S.; Arab Verdugo, Juan Pablo; Liu, M.; Amrollahi, P.; Wan, M.; Fan, J.; Nakao, Y.; Pose, E.; Navarro Corcuera, A.; Dasgupta, D.; Liao, C. Y.; He, L.; Mauer, A. S.; Avitabile, E.; Ventura Cots, M.; Bataller, R. A.; Sanyal, A. J.; Chalasani, N. P.; Heimbach, J. K.; Watt, K. D.; Gores, G. J.; Gines, P.; Kamath, P.S.; Simonetto, D. A.; Hu, Tony Y. Shah, V. H.; Malhi, H.
  • Thumbnail Image
    Item
    Comparative effectiveness of different corticosteroid regimens in severe alcohol-associated hepatitis
    (Lippincott Williams and Wilkins, 2024) Islam, Alvi Husni; Díaz, Luis Antonio; Idalsoaga Ferrer, Francisco Javier; Guizzetti, Leonardo; Mortuza, Rokhsana; Dunn, Winston; Singal, Ashwani K.; Simonetto, Douglas; Ramírez Cadiz, Carolina; Zhang, Wei; Qian, Steve; Cabezas, Joaquín; Sarin, Shiv K.; Maiwall, Rakhi; Jalal, Prasun K.; Higuera De La Tijera, Fátima; Skladany, Lubomir; Bystrianska, Natalia; Rincón, Diego; Chacko, Kristina R.; Ventura Cots, Meritxell; García Tsao, Guadalupe; Abraldes, Juan G.; Kamath, Patrick S.; Arrese Jiménez, Marco; Shah, Vijay; Bataller, Ramón; Arab Verdugo, Juan Pablo
  • Thumbnail Image
    Item
    Concurrent nonalcoholic fatty liver disease and type 2 diabetes: diagnostic and therapeutic considerations
    (2019) Arrese Jiménez, Marco; Barrera Martínez, Francisco José; Triantafilo, Nicólas; Arab Verdugo, Juan Pablo; Arrese Jiménez, Marco; Barrera Martínez, Francisco José; Triantafilo, Nicólas; Arab Verdugo, Juan Pablo
  • Thumbnail Image
    Item
    Consenso chileno de prevención, diagnóstico y tratamiento de la diarrea asociada a Clostridium difficile
    (2016) Hernández Rocha, Cristián Antonio; Ajenjo Henríquez, María Cristina; Quera R.; Quintanilla M.; Lubascher J.; Jemenao M.; Ibáñez Lazo, Patricio Fernando; Álvarez Lobos, Manuel; Diomedi A.; Marcotti A.; Acuña M.; Arab Verdugo, Juan Pablo; Riquelme Segovia, Alfredo; Candia R.; Carvajal S.; Hernández Rocha, Cristián Antonio; Ajenjo M.; Quera R.; Quintanilla M.; Lubascher J.; Jemenao M.; Ibáñez P.; Álvarez Lobos, Manuel; Diomedi A.; Marcotti A.; Acuña M.; Arab Verdugo, Juan Pablo; Riquelme Segovia, Alfredo; Candia R.; Carvajal S.
  • No Thumbnail Available
    Item
    Direct antivirals for the treatment of chronic hepatitis C virus infection. Experience in 106 patients.
    (2017) Soza Ried, Alejandro; Benítez Gajardo, Carlos Esteban; Barrera Álvarez, Francisco Benjamín; Monrroy Bravo, Hugo Alfonso; Vargas Domínguez, José Ignacio; Arab Verdugo, Juan Pablo; Arrese Jiménez, Marco Antonio; Sarmiento, V.; Fuster, F.
    Background: The availability of direct-acting antivirals (DAA) for the treatment of chronic hepatitis C virus (HCV) infection is just starting to expand in Chile. Aim: To report the initial experience of patients treated with DAA and their evolution after treatment. Material and Methods: Prospective cohort study, from June 2013 to August 2016 of patients treated with DAA for HCV in three clinical centers. The presence of cirrhosis, clinical and laboratory features; adverse events (AE) and post-treatment changes in liver function were evaluated. Sustained viral response at 12 weeks post-treatment (SVR12) was determined. Results: One hundred six patients aged 58 +/- 13 years, 54% males, were included. HCV genotype 1b was present in 88% and 47% had cirrhosis. Treatment regimens were asunaprevir + daclatasvir (DCV) in 17% of patients, paritaprevir / ritonavir / ombitasvir + dasabuvir in 33%, sofosbuvir (SOF) + DCV in 19%, and SOF + ledipasvir in 30%. Twenty five percent of patients used generic drugs. SVR12 was 92.1%, with no differences between generic and brand-name drugs. Serious AE were recorded in 22% of patients, being more common in those with cirrhosis (34% vs 11.5%, p < 0.01). At 12 weeks post-treatment follow-up, there was a decrease in aminotransferase values (p < 0.01), improvement in Child-Pugh score (5.9 vs. 5.5, p = 0.03) and decreased presence of ascites (p = 0.02). Conclusions: In our setting, DAA for HCV was highly effective and safe in non-cirrhotic patients. Hepatic function and inflammation improved at 12 weeks of follow-up. AE were common in patients with cirrhosis, suggesting that these patients should be treated by experienced teams. Generic drugs had similar effectiveness compared to originals.